These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6102461)

  • 21. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term treatment of tardive dyskinesia.
    Jus A; Jus K; Fontaine P
    J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-dergocrine (hydergine) in the treatment of tardive dyskinesia.
    Rastogi SC; Blowers AJ; Gibson AC
    Psychol Med; 1982 May; 12(2):427-9. PubMed ID: 6124989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment.
    Aman MG; Singh NN
    J Ment Defic Res; 1985 Jun; 29 ( Pt 2)():187-95. PubMed ID: 2863380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tardive dyskinesia: pergolid, a possible therapeutic option].
    Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
    Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia: review and update.
    Klawans HL; Goetz CG; Perlik S
    Am J Psychiatry; 1980 Aug; 137(8):900-8. PubMed ID: 6106395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with dimethylaminoethanol (deanol) in neuroleptic induced tardive dyskinesia].
    Kocher R; Hobi V; Linder M; Studer K
    Schweiz Arch Neurol Neurochir Psychiatr; 1980; 126(1):103-9. PubMed ID: 6106283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A therapeutic approach to tardive dyskinesia.
    Fahn S
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):19-24. PubMed ID: 2858474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
    Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithium carbonate in the treatment of movement disorders. A critical review.
    Yassa R; Ananth J
    Int Pharmacopsychiatry; 1980; 15(5):301-8. PubMed ID: 6114936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroleptic-induced tardive dyskinesia.
    Jenner P; Marsden CD
    Acta Psychiatr Belg; 1987; 87(5):566-98. PubMed ID: 2897761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine in tardive dyskinesia: observations from human and animal model studies.
    Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic and antidyskinetic properties of ergot dopamine agonists.
    Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 23():397-403. PubMed ID: 7395624
    [No Abstract]   [Full Text] [Related]  

  • 39. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of tardive dyskinesia with vitamin E.
    Egan MF; Hyde TM; Albers GW; Elkashef A; Alexander RC; Reeve A; Blum A; Saenz RE; Wyatt RJ
    Am J Psychiatry; 1992 Jun; 149(6):773-7. PubMed ID: 1350428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.